Please assess the completion status of the following clinical trial:

Trial Title: NoAL (HPMC) in Combination With Oxymetazoline in Patients With Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients~* Age ≥ 18 and ≤ 50 years~* Moderately severe / severe persistent allergic rhinitis~* Positive skin prick test for perennial aero-allergens~* Active symptoms with prominent congestion at the time of inclusion~Exclusion Criteria:~* Subjects with pollen sensitization during the respective pollen season~* Subjects with arterial hypertension, arrhythmia or evidence of heart ischemia~* Subjects with other serious chronic comorbidities and bad therapeutic control~* Subjects with nasal polyposis~* Flu-like episode during the past 30 days~* Subjects unable to give informed consent~* Subjects with any of the contra-indications of oxymetazoline or NoAL~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): One puff of oxymetazoline immediately followed by one puff of hydroxyl-propyl-methyl cellulose powder, morning \& evening, for 8 days.
- Group B (Type: PLACEBO_COMPARATOR): One puff of oxymetazoline immediately followed by one puff of placebo, morning \& evening, for 8 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).